Estimation of MDA, CRP and Some hematological parameters in the mature Cypriot Thalassemia patients

  • Ahmed Abduljalal abduljabbar Department of Fish Resource & Aquatic Animals, Salahaddin University-Erbil, Kurdistan Region, Iraq
  • Güldal Mehmetçik Head of Biochemistry Dep. Near east university, Nicosia, North Cyprus/turkey
Keywords: Fluoxetine, Depression, Liver, Kidney, Cerebrum.


     Thalassemia is a blood disorder has been known to passes down by parent to their offspring. The root of this disorder mainly returns to the Mediterranean Countries. Degradation of erythrocytes results in a thalassemia disease as a result of producing defeated Hemoglobin Molecules, due to changes occurring in their DNA structure like insertion or deletion. For decades the only medical treatment those patients had is getting blood gave way by healthy volunteers. As a result of this process, they receive lots of Iron minerals possibly causing oxidative Stress, Inflammation and splenomegaly. The aim of the present work aimed to estimate the C-Reactive Proteins (CRP) as Biomarker of Inflammation, Serum Ferritin as Biomarker of Iron overload and MDA as A biomarker of oxidative Stress in patients B- thalassemia then comparing their data to healthy normal volunteers. The study group consisted of 24 thalassemia patients and 24 control groups. The blood samples of β-thalassemia cases were collected in thalassemia center In Dr.Burhan Nalbantoğlu Government Hospital/ Cyprus. After centrifugation, Aliquots of serum and plasma has been stored for the later estimation CRP, MDA and serum ferritin. Our data shows that the levels of C-reactive protein (1.350 ± 1.142 vs 0.325 ± 0.398; p<0.001), MDA (7.734 ± 1.557 vs 5.638 ± 1.219; p<0.001) and serum ferritin (617.92 ± 238.63 vs 433.82 ± 228.61; p=0.016) were significantly greater in contrast to same parameters of healthy controls. overall, our study proved again that examining levels of CRP, MDA and serum ferritin could serve as good indicators of the risks possibly faces those patients, knowledge about the status of those parameters could offer Some Helpful Knowledge assisting health professionals in better management   patients with β-Thalassemia.


Awadallah, S. M., Atoum, M. F., Nimer, N. A., & Saleh, S. A. (2012). Ischemia modified albumin: An oxidative stress marker in β-thalassemia major. Clinica Chimica Acta, 413(9–10), 907–910.
Aziz, B. N., Al-Kataan, M. A., & Ali, W. K. (2009). Lipid peroxidation and antioxidant status in B-Thalassemic patients: effect of iron overload. Iraqi Journal of Pharmaceutical Sciences, 18(2), 8–14.
Breiterman-White, R. (2006). C-reactive protein and anemia: implications for patients on dialysis. Nephrol Nurs J, 33(5), 555–558.
Cappellini, M. D. (2006). A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 107(9), 3455–3462.
Chin, J. Y., Kuan, J. Y., Lonkar, P. S., Krause, D. S., Seidman, M. M., Peterson, K. R., … Glazer, P. M. (2008). Correction of a splice-site mutation in the beta-globin gene stimulated by triplex-forming peptide nucleic acids. Proceedings of the National Academy of Sciences, 105(36), 13514–13519.
Cighetti, G., Duca, L., Bortone, L., Sala, S., Nava, I., Fiorelli, G., & Cappellini, M. D. (2002). Oxidative status and malondialdehyde in beta-thalassaemia patients. European Journal of Clinical Investigation, 32 Suppl 1, 55–60.
Fiers, W., Beyaert, R., Declercq, W., & Vandenabeele, P. (1999). More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene, 18, 7719–7730.
Fucharoen, S., & Winichagoon, P. (1997). Hemoglobinopathies in Southeast Asia: Molecular Biology and Clinical Medicine. Hemoglobin.
Gunarsih, A., Amalia, P., & Boediman, I. (2012). Paediatrica Indonesiana. Paediatrica Indonesiana, 52(3), 125–131.
Hage, F. G., McCrory, M. A., & Szalai, A. J. (2009). C-reactive protei and cardiovascular disease: Lessons learned from studying genetically engineered mice. C-Reactive Protein: New Research.
Hayes, J. D., & McLellan, L. I. (1999). Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. In Free Radical Research (Vol. 31, pp. 273–300).
Jokhio, R., Khan, Y., Chughtai, L. A., & Mughal, Z. (2009). C-Reactive ( Crp ) Protein in Transfusion Dependent Thalassaemic Patients. Pak J Physiol, 5(2), 20–23.
Kanavaki, I., Makrythanasis, P., Lazaropoulou, C., Tsironi, M., Kattamis, A., Rombos, I., & Papassotiriou, I. (2009). Soluble endothelial adhesion molecules and inflammation markers in patients with β-thalassemia intermedia. Blood Cells, Molecules, and Diseases, 43(3).
Kikugawa, K., Kosugi, H., & Asakura, T. (1984). Effect of malondialdehyde, a product of lipid peroxidation, on the function and stability of hemoglobin. Archives of Biochemistry and Biophysics, 229(1), 7–14.
Livrea, M. a, Tesoriere, L., Pintaudi, a M., Calabrese, a, Maggio, a, Freisleben, H. J., … Bongiorno, a. (1996). Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood, 88(9), 3608–3614.
Lynch S1. (2012). Influence of infection/inflammation, thalassemia and nutritional status on iron absorption. Int J Vitam Nutr Res. 77(3):217-23.
Meral, A., Tuncel, P., Surmen-Gur, E., Ozbek, R., Ozturk, E., & Gunay, U. (2000). Lipid peroxidation and antioxidant status in beta-thalassemia. Pediatr Hematol Oncol, 17(8), 687–93.
Nesto R1. (2004). C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med., 21.(8), 810–7.
Nasr, M. R., Ebrahim, N. A., & Salahedin, O. (2012). Growth pattern in children with beta-thalassemia major and its relation with serum ferritin, IGF1 and IGFBP3. Journal of Clinical and Experimental Investigations.
Nicholls, D. G., & Budd, S. L. (2000). Mitochondria and Neuronal Survival. Physiological Reviews, 80(1), 315–360.
Niedernhofer, L. J., Daniels, J. S., Rouzer, C. A., Greene, R. E., & Marnett, L. J. (2003). Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. Journal of Biological Chemistry, 278(33), 31426–31433.
Weatherall, D. J., Akinyanju, O., Fucharoen, S., Oliveri, N., & Musgrove, P. (2006). Inherited disorders of hemoglobin. In Disease Control Priorities in Developing Countries (pp. 663–680).
Winichagoon, P., Fucharoen, S., Chen, P., & Wasi, P. (2000). Genetic factors affecting clinical severity in beta-thalassemia syndromes. J Pediatr Hematol Oncol, 22(6), 573–580.
Walter, P. B., Fung, E. B., Killilea, D. W., Jiang, Q., Hudes, M., Madden, J., … Harmatz, P. (2006). Oxidative stress and inflammation in iron-overloaded patients with β-thalassaemia or sickle cell disease. British Journal of Haematology.
How to Cite
Abduljalal abduljabbar, A. and Mehmetçik, G. (2019) “Estimation of MDA, CRP and Some hematological parameters in the mature Cypriot Thalassemia patients”, Zanco Journal of Pure and Applied Sciences, 31(s4), pp. 143-149. doi: 10.21271/zjpas.31.s4.23.